Medigen Biotechnology Corp. (3176.TWO) is a Taiwan-based biopharmaceutical company that develops, manufactures and commercializes vaccines and biotherapeutics. The company offers a portfolio of recombinant protein vaccines, including its flagship Medigen COVID-19 vaccine (MVC-COV1901), influenza vaccines, and candidates for dengue fever, hand-foot-mouth disease, and third-generation COVID-19 boosters; it also provides contract development and manufacturing organization (CDMO) services for biologics, monoclonal antibodies, and cell therapies, along with diagnostic kits and related research tools. Medigen operates primarily in the biotechnology and vaccine segment, targeting government health agencies, hospitals, and pharmaceutical partners in Asia, with expanding efforts into global markets including Europe and the Americas.
Founded in 1999 and headquartered in Taipei, Taiwan, the company maintains research and production facilities in Taiwan and focuses on innovative vaccine platforms such as protein subunit and adenovirus vector technologies. Its subsidiaries include Medigen Vaccine Biologics Corp., which handles large-scale manufacturing, and it collaborates with international partners like the International Vaccine Institute and Dynavax Technologies for technology transfer and clinical development. Medigen serves public health sectors and commercial biotech firms, with products distributed across Taiwan, Indonesia, Thailand, and other regions through strategic supply agreements.
In the last two years, Medigen has advanced several key initiatives, including the commercialization of its MVC-COV1901 vaccine with regulatory approvals in Taiwan and export deals to multiple Southeast Asian countries; it secured a major partnership with the Taiwan government for domestic vaccine stockpiling and launched Phase III trials for its dengue fever vaccine candidate. The company completed a significant funding round in 2024 via equity issuance to support CDMO expansion and announced a strategic alliance with a European biotech firm for next-generation mRNA vaccine co-development in late 2025. Additionally, Medigen reorganized its operations to enhance GMP-compliant facilities for international tenders, positioning it for growth in the post-pandemic biopharma market.